Alembic Pharmaceutical’s stock closed at ₹823.15 on the BSE, down 0.70 paise, or 0.085%, after the company reported Q1 net profit of ₹172 cr, an 11.7% jump from ₹154 cr a year earlier, and revenue of ₹2,150 cr, up 26% on the same period.
But the company’s operating margin slipped to 15.5% from 16.4% YoY, a sign that higher cost of goods and marketing are eroding profitability even as top‑line growth accelerates.
Earning before interest, taxes, depreciation and amortisation (EBITDA) rose 18.6% to ₹333 cr, yet the company’s post‑R&D EBITDA saw a 21% jump thanks to a leaner cost base and added leverage in its US branded portfolio.
The US formulation arm grew 49% YoY, driven by new launches, and now accounts for a growing share of the company’s revenue stream. This momentum comes after the firm received a clean exit from the USFDA inspection of its Vadodara bioequivalence plant.
Looking ahead, Alembic has not issued new guidance but the board’s focus on the U.S. market and a continued push in R&D pipeline suggest a potential upside once the company consolidates its international footprint.